PENGARUH PENGGUNAAN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR DAN ANGIOTENSIN RECEPTOR BLOCKER TERHADAP MORTALITAS PASIEN COVID-19 DENGAN KOMORBIDITAS PENYAKIT KARDIOVASKULAR TINJAUAN SISTEMATIS

• Main Author: Aulia Setya Nurrachmah, (Author)
• Format: Book
• Published: 2021-01-12.
• Subjects: Thesis; NonPeerReviewed
• Online Access: Link Metadata
• Notes: http://repository.upnvj.ac.id/9179/1/ABSTRAK.pdf; http://repository.upnvj.ac.id/9179/23/AWAL.pdf; http://repository.upnvj.ac.id/9179/3/BAB%201.pdf; http://repository.upnvj.ac.id/9179/4/BAB%202.pdf; http://repository.upnvj.ac.id/9179/5/BAB%203.pdf; http://repository.upnvj.ac.id/9179/6/BAB%204.pdf; http://repository.upnvj.ac.id/9179/7/BAB%205.pdf; http://repository.upnvj.ac.id/9179/8/DAFTAR%20PUSTAKA.pdf; http://repository.upnvj.ac.id/9179/9/RIWAYAT%20HIDUP.pdf; http://repository.upnvj.ac.id/9179/10/LAMPIRAN.pdf; http://repository.upnvj.ac.id/9179/11/ARTIKEL%20KI.pdf
• Keywords: RM Therapeutics. Pharmacology

Background: COVID-19 has a high prevalence in patients with underlying comorbidity, such as cardiovascular disease. Angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy in COVID-19 patients with cardiovascular disease comorbidity gives rise to a controversy for ACEI and ARB could upregulate angiotensin-converting enzyme 2 (ACE2) expression in a previous study in animals. ACE2 is considered a receptor for SARS-CoV-2, suggesting that ACEI and ARB consumption would worsen the patient's condition. This systematic review aims to analyze the effects of ACEI and ARB on the mortality of COVID-19 patients with cardiovascular disease comorbidity. Methods: This systematic review was conducted from July to August 20, 2020 for the literature collection. The literature were collected from PubMed, Google Scholar, and Science Direct, according to Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols (PRISMA-P). Results: There were eight data obtained. Three literatures resulted in lower mortality in COVID-19 patients with cardiovascular disease comorbidity who consumed ACEI/ARB. Five literatures concluded that there was no significant difference between COVID-19 patients who consumed ACEI/ARB and who did not. Conclusion: The mortality in COVID-19 patients with cardiovascular disease comorbidity who consumed ACEI/ARB is lower, according to three literatures, therefore, the therapy using ACEI/ARB should be continued because it is more beneficial to keep consuming ACEI/ARB than to stop consuming them.